GSK-3β inhibitor 1

Overview

GSK-3β inhibitor 1 (compound 3a) inhibits GSK-3β with an IC 50 of 4.19 nM. GSK-3β inhibitor 1 demonstrates high antidiabetic efficacy in obese Streptozotocin ( HY-13753 )-treated rats.

Application

Products | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Depression | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Obesity | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Stem Cell/Wnt | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > GSK-3

Product Information

• Catalog No.: HY-126144
• CAS No.: 187325-53-7
• Molecular Formula: C14H10N2O
• Molecular Weight: 222.25
• Purity: 98.82%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (11.25 mM); Clear solution
• Availability: In-stock

Source

Original product source